Skip to main content
. 2013 Jul 8;169(1):137–145. doi: 10.1111/bjd.12266

Fig 4.

Fig 4

Target Plaque Severity Score (TPSS) – induration, erythema and scaling subscore changes from baseline for tofacitinib ointment 1 vs. vehicle 1 (a, c, e) and ointment 2 vs. vehicle 2 (b, d, f) (full analysis set, no imputation). *Statistically significant (one-sided 90% upper confidence limit < 0); standard error bars may overlap at the prespecified statistical significance level. LSM, least squares mean.